Division of Human Genetics and Metabolism, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; Department of Pediatrics and Adolescent Medicine, University Medical Center Göttingen, Germany.
Mol Genet Metab. 2018 Mar;123(3):337-346. doi: 10.1016/j.ymgme.2018.01.005. Epub 2018 Jan 31.
Multiple sulfatase deficiency (MSD) is an ultra-rare neurodegenerative disorder that results in defective sulfatase post-translational modification. Sulfatases in the body are activated by a unique protein, formylglycine-generating enzyme (FGE) that is encoded by SUMF1. When FGE is absent or insufficient, all 17 known human sulfatases are affected, including the enzymes associated with metachromatic leukodystrophy (MLD), several mucopolysaccharidoses (MPS II, IIIA, IIID, IVA, VI), chondrodysplasia punctata, and X-linked ichthyosis. As such, individuals demonstrate a complex and severe clinical phenotype that has not been fully characterized to date. In this report, we describe two individuals with distinct clinical presentations of MSD. Also, we detail a comprehensive systems-based approach to the management of individuals with MSD, from the initial diagnostic evaluation to unique multisystem issues and potential management options. As there have been no natural history studies to date, the recommendations within this report are based on published studies and consensus opinion and underscore the need for future research on evidence-based outcomes to improve management of children with MSD.
多种硫酸酯酶缺乏症(MSD)是一种超罕见的神经退行性疾病,导致硫酸酯酶翻译后修饰缺陷。体内的硫酸酯酶由一种独特的蛋白质,即甲酰甘氨酸生成酶(FGE)激活,该酶由 SUMF1 编码。当 FGE 缺失或不足时,所有 17 种已知的人类硫酸酯酶都会受到影响,包括与异染性脑白质营养不良(MLD)、几种黏多糖贮积症(MPS II、IIIA、IIID、IVA、VI)、软骨发育不良点状、和 X 连锁鱼鳞病相关的酶。因此,个体表现出复杂而严重的临床表型,迄今为止尚未得到充分描述。在本报告中,我们描述了两名具有不同 MSD 临床表现的个体。此外,我们详细介绍了一种基于系统的综合方法来管理 MSD 个体,从初始诊断评估到独特的多系统问题和潜在的管理选择。由于迄今为止尚无自然病史研究,因此本报告中的建议基于已发表的研究和共识意见,并强调需要对基于证据的结果进行未来研究,以改善 MSD 儿童的管理。